Welcome to

Our Event


Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our Next Gen Immuno-Oncology Congress from past 2 years had gathered the professionals across the globe to deliver such latest developments.


Awesome Image

2 DAY EVENT

50 SPEAKERS

250 TICKETS

10 Hours of Networking

Agenda

Time Speaker Name Presentation Title
09:05 Michelle Morrow Keynote: Bispecific Antibodies to Deliver the Next Immuno-Oncology Breakthrough
09:05 Kandeepan Ganeshaligam Checkpoint inhibitors as a therapeutic strategy in Oncology
09:35 Stephen Beers Optimising anti-cancer therapy with immune stimulatory antibodies: When opposites co-act
10:05 David Giljohann Innate immune activators- spherical nucleic acid tlr9 in combination with checkpoint inhibitors
11:25 Will Arends Immuno-oncology and the Patent Maze
11:25 Dr. Mark Creighton-Gutteridge GSK’s Oncology Cell Therapy
11:55 Thomas Valerius Improving recruitment of myeloid effector cells for antibody therapy
12:25 Awesome Image Livija Deban Microbial anti-cancer therapy: live attenuated Salmonella for treatment of solid tumours
12:25 Awesome Image Lucia Pattarini Bispecific antibody-based therapeutics to modulate T cell activation
13:55 John Maudsley Vaccines: the Next Generation I-O: addressing the needs
13:55 Sophia Karagiannis Monoclonal antibody approaches for triple-negative breast cancer
13:55 Zoe Johnson PI3Kd: A new era in immuno-oncology
14:35 Heinz Lubenau Oral T-Cell Therapies for the Treatment of Cancer Patients
15:35 Jeanette Leusen IgA recruits neutrophils for tumorkill, combination with innate checkpoint inhibition
15:35 Steven Schellings Bringing CAR-t to treatment centers: lessons learned
Time Speaker Name Presentation Title
09:05 Stefan Glueck Keynote: Why are we so late in treatment of breast cancer using ICI?
09:05 Awesome Image Andrew Sewell Keynote: What can we learn by dissecting immunotherapy successes?
09:35 Alex Blyth Using cancer killing neutrophils to destroy all solid tumours
11:25 Lindy Durrant Stress induced post translational modifications are good targets for cancer immunotherapy
12:25 Anneli Andersson Validation markers for tumor derived T-cell sub-populations
Full Name *
Email Id *

Company *
Job Title *

Country Code *
Phone Number *

Country *




Advisors

Eugene	Zhukovsky
Eugene Zhukovsky

CSO

Biomunex Pharmaceuticals

Jeanette	Leusen
Jeanette Leusen

Group Leader, Tumor Immunology

UMC Utrecht

Sophia Karagiannis
Sophia Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy

King's College London

Stefan Glueck
Stefan Glueck

Vice President, Global Medical Affairs Solid Tumors, Immuno-Oncology and Early Assets, Clegene

Celgene

USA



Our Speakers

Eugene	Zhukovsky
Eugene Zhukovsky

CSO

Biomunex Pharmaceuticals

Jeanette	Leusen
Jeanette Leusen

Group Leader, Tumor Immunology

UMC Utrecht

Lindy Durrant
Lindy Durrant

Professor-Cancer Immunotherapy

The University of Nottingham

Matthias Peipp
Matthias Peipp

Professor, Group Leader

University of Kiel

Livija Deban
Livija Deban

VP Immunology and Oncology

Prokarium

Shailendra Singh (Shelly)
Shailendra Singh (Shelly)

Chief Operating Officer

MarketsandMarkets

Sophia Karagiannis
Sophia Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy

King's College London

Thomas Valerius
Thomas Valerius

Professor-Department of stem cell and immunotherapy

Kiel Life Science, Germany


Know All Speakers


Event Sponsors

Platinium

Diamond

Gold

Silver

Sponsors & Exhibitors

Official Logistics Partner


Become Sponsor Know All Sponsors


Media Partners


Supporting Association



Submit your Poster Presentation

Venue

London, UK


View on Map
Image Gallery
Loading...